Plain-English translation of NCT06428409 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Colorectal Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is a Phase 1/2 study testing a new medication called for people with advanced gastrointestinal cancers — specifically colorectal, pancreatic, or bile duct cancer — that either cannot be removed by surgery or has spread throughout the body. The trial will give some participants the medication alone, while others will receive it combined with other established cancer treatments. Researchers want to understand how safe and effective this approach is, and whether combining it with other drugs works better.
Advanced gastrointestinal cancers are difficult to treat, and current options don't work well enough for all patients. This trial exists to see whether this new medication — possibly combined with treatments already used in cancer care — can help more people with these cancers achieve better outcomes.
You likely qualify if…
You likely don't qualify if…
You will visit the research center regularly to receive treatment infusions every 2 to 3 weeks, depending on which medication combination you are assigned to. You will continue receiving treatment until your cancer stops responding or the side effects become too difficult to manage. The study includes blood tests, imaging scans, and check-ins to monitor how well the treatment is working and how you are tolerating it. Depending on your treatment group, you may receive the medication alone or combined with one or more other cancer drugs, some continuing for up to 2 years.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
United States